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Abstract
The sodium pump (Na,K-ATPase; EC 3.6.1.37) of animal cell membranes is the enzyme responsible for the
maintenance of membrane potential, for the function of secondary active transporters, and for osmoregulation of the cell.
Since inhibition of the enzyme by cardiac glycosides results in increased contractility of the heart muscle and increased blood
pressure, we were interested in whether there is a correlation between hypertension and expression of the various isoforms of
the sodium pump. In addition, we also examined the expression of the isoforms of the sarcoplasmic and plasma membrane
Ca2-ATPase, the Na/Ca2- and Na/H-exchangers, and Na channel and Ca2 channel isoforms. Total mRNA was
isolated from 50 mg tissue from the right atrium of hypertensive and normotensive patients who were undergoing cardiac
surgery. After reverse transcription and subsequent amplification of ion transporter-specific cDNA fragments by polymerase
chain reaction (PCR) in the presence of [K-32P]dCTP, quantification of the amplified fragments was carried out by the
Phosphorimager technique. The data obtained show that the Kl subunit mRNA is expressed similarly in normotensive and
hypertensive patients. The amount of K2 subunit mRNA, however, is increased 5-fold in hypertensive patients. In the same
group, the amount of K3 isoform is also significantly increased, although not as dramatically as the K2 isoform. Besides the
Na,K-ATPase isoforms, a significant increase in the expression of mRNA for the Na/Ca2-exchanger and the plasma
membrane Ca2-ATPase isoforms was detected. It is possible that the observed changes in mRNA expression for these ion
transporters reflect compensatory mechanisms to overcome a defective Na and Ca2 metabolism in the tissues of
hypertensive patients or reflect defects directly involved in the cause of hypertension. The expression of mRNA for all other
transporters investigated was unaltered. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
In industrialized countries, morbidity, invalidism
and mortality are often closely associated with the
phenomenon of elevated blood pressure, i.e., arterial
hypertension. Hypertension is the main risk factor
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for heart insu⁄ciency, stroke, claudicatio intermit-
tens or kidney artery defects. Nevertheless, for only
5% of these patients is the primary cause of hyper-
tension known, which is mostly associated with de-
fects in kidney function. Thus, for the vast majority
of hypertension cases, the primary defect and its mo-
lecular basis are unknown. These unde¢ned cases of
hypertension are referred to as primary (or essential)
hypertension. Primary hypertension seems to be an
inheritable disease. This conclusion is based on the
fact that more than 70% of all patients with primary
hypertension have a positive family history of the
disease. In several cases, hypertension follows poly-
genic patterns of inheritance: the genes involved
manifest the defect ‘hypertension’ via so-called inter-
mediate phenotypes. Besides involving neurohumoral
systems, these could be quantitative and also quali-
tative alterations in membrane-embedded ion trans-
porting proteins. Whether independent or combined
with environmental factors, these intermediate phe-
notypes could lead to the increase in arterial blood
pressure.
In this respect, sodium chloride would be an envi-
ronmental factor that could become a risk factor
for hypertension when its metabolism does not fol-
low the normal physiological pattern. An increased
sodium concentration in tissues and cells has been
reported to be associated with the phenomenon
of hypertension [1] and on many occasions it was
speculated that some defect in a sodium transporting
system might cause this nonphysiological eleva-
tion. The Na/H-exchanger seems to be involved
in this phenomenon [2]. A G-protein-mediated over-
activation of the exchanger might cause an eleva-
tion of cytosolic sodium, leading to a secondarily
induced elevation of the Ca2 concentration in the
cytosol and resulting in an increase in muscle con-
tractility and an associated increase in blood pres-
sure [2].
Despite this plausible explanation, it remains a fact
that the major sodium-extruding ion transporter
present in all animal cell plasma membranes is the
sodium pump. Changes in its activity could also re-
sult in changes in contractility of arteries or heart
muscle, something often proposed by various inves-
tigators [3]. This and the fact that various sodium
pump isoforms are expressed in various tissues [4]
lead to the question of whether changes in activity
or expression of sodium pump isoforms might be
associated with the phenomenon of hypertension.
The study presented here addresses this question by
investigating the expression of sodium pump iso-
form-speci¢c mRNA in the heart muscle of normo-
tensive and hypertensive patients.
2. Materials and methods
2.1. Ethics
The study was approved by the Ethics Commis-
sion of the Justus-Liebig-University of Giessen and
conforms with the principles outlined in the declara-
tion of Helsinki (BMJ 1964; ii :177). All patients
Table 1
Patient data
Patient Sex Age (years) Weight (kg) Height (cm) Blood pressure systolic/diastolic (mmHg/mmHg)
H1 Male 66 82 175 Hypertensive 190/100
H2 Female 72 56 154 Hypertensive 190/100
H3 Male 68 80 174 Hypertensive 160/90
H4 Male 44 96 196 Hypertensive 160/80
H5 Male 55 96.5 186 Hypertensive 170/100
N1 Male 48 80 175 Normotensive 120/80
N2 Male 54 75 175 Normotensive 120/70
N3 Male 69 89 181 Normotensive 120/80
N4 Male 65 87.7 174 Normotensive 130/70
N5 Male 52 85 179 Normotensive 120/80
All patients investigated were scheduled to undergo surgery due to coronary artery disease or aortic valvular dysfunction. Tissue sam-
ples of approximately 50 mg were taken from the right atrial appendage, freed from blood in NaCl solution and immediately frozen
in liquid nitrogen.
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were informed and had agreed to participate in the
study.
2.2. Tissue preparation
All patients investigated were scheduled to under-
go surgery due to coronary artery disease or aortic
valvular dysfunction. They were between 44 and 72
years of age, and included ¢ve normotensive males,
four hypertensive males, and one hypertensive female
(Table 1). Tissue samples of approximately 50 mg
were taken from the right atrial appendage after
purse-string suture prior to venous cannulation. Im-
mediately after removal, tissue was freed from blood
in isotonic NaCl and was then immediately frozen in
liquid nitrogen.
2.3. RNA extraction
Total cell RNA was isolated by the Micro RNA
Isolation kit (Stratagene, Heidelberg, Germany),
which is a guanidinium iso-thiocyanate-phenol-
chloroform isolation method. The resultant RNA
pellet was dried in a vacuum centrifuge and re-
suspended in 20 Wl of RNase-free water (aqua ad
injectabilia, Ampuwa, Fresenius, Bad Homburg,
Germany). In order to eliminate genomic DNA,
which would falsify the results of the PCR ampli-
¢cation, 0.5 Wl ( = 3.75 units) of DNaseI (Pharmacia
Biotech, Uppsala, Sweden) was added and the
mixture was incubated for 10 min at 37‡C. After-
wards, the sample was cooled on ice and RNA
was isolated a second time using the Micro RNA
Isolation kit. Then the pellet was dried in vacuum
again and resuspended in 35^50 Wl of the RNase-
free water mentioned above. The RNA concen-
tration in the solution was determined in a spec-
trophotometer by measuring the absorbance at
260 nm.
2.4. cDNA synthesis
First-strand cDNA was synthesized from 30 Wg of
total RNA using oligo(dT)15 primer (4 WM), dNTP
mixture (500 WM of each dNTP), 400 U Moloney
murine leukemia virus reverse transcriptase (Amer-
sham, Braunschweig, Germany) and bu¡er supplied
by the manufacturer in a 50-Wl reaction volume for
1 h at 37‡C. The reaction was stopped by incubation
at 95‡C for 5 min, and the cDNA was stored at
320‡C until use.
2.5. PCR conditions
Polymerase chain reaction (PCR) was performed
in a Cyclone Temperature Cycler (Integra Bioscien-
ces, Fernwald, Germany). A total of 100 Wl of the
PCR mixture contained 1 Wl ¢rst-strand cDNA, 200
WM of each dNTP, 20 pmol of each primer, 1.8 pmol
(5.4 WCi) [K-32P]dCTP (Hartmann Analytik,
Braunschweig, Germany), 2 U T£-Polymerase (Bio-
zym Diagnostik, Oldendorf, Germany), 1.5 mM
MgCl2 and bu¡er supplied by the manufacturer.
To minimize error, a mixture of all components
was made and an aliquot of this was taken for
each reaction. The PCR was started with an initial
denaturation (5 min at 95‡C), followed by ampli¢ca-
tion with 25 cycles each consisting of the following
steps: 30 s at 94‡C (denaturation), 1 min at 60‡C
(annealing), and 2 min at 72‡C (polymerization). In
order to control the quality of each PCR ampli¢ca-
tion, a standard template of a de¢ned initial amount
was ampli¢ed under the same conditions. The oligo-
nucleotide primers used are given in Table 2. They
were designed for an annealing temperature of 60‡C
[5].
2.6. Agarose gel electrophoresis and radioactivity
determinations
After ampli¢cation, 10 Wl of the PCR products
were size-fractionated by electrophoresis in a 1% aga-
rose gel and then stained with ethidium bromide. The
product bands were visualized under ultraviolet light,
and the agarose gel was ¢xed in 7% trichloroacetic
acid (TCA) and dried. The gel was exposed to Ko-
dak X-Omat AR X-ray ¢lm using an intensifying
screen for 2 to 48 h at 380‡C to check the exposure
time. A quantitative evaluation was performed with
the use of a Phosphorimager BAS 1000 (Raytest Iso-
topenmeMgera«te, Straubenhardt, Germany). Using
the radioactivity measured and the known amount
of [K-32P]dCTP, the quantity of the ampli¢ed double
strands was calculated.
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2.7. Calculation of the original mRNA/cDNA content
in the cardiac tissue used for the analysis
In an optimal situation, the cDNA copies pro-
duced in each PCR cycle are twice as many as the
original number of copies prior to the ampli¢cation.
Thus, ideally, the number of cDNA copies follows an
exponential growth rate 2n and can be described by
the formula
Nn  N0U2n 1
In this formula, n is the number of PCR cycles, Nn
the concentration of cDNA after the ampli¢cation,
and N0 the cDNA concentration prior to the ampli-
¢cation. This exponential PCR ampli¢cation of
cDNA and the linear correlation between product
concentration and original cDNA content allow
one to calculate the original single-stranded (ss)DNA
( = mRNA) quantity prior to the PCR ampli¢cation.
Nevertheless, several parameters might in£uence the
PCR and it is therefore necessary to de¢ne for the
ampli¢cation an e⁄ciency factor E. Taking this fac-
tor into consideration, the relationship in Eq. 1 is
now written as
Nn  N01 En 2
and therefore
logNn  log1 EUn logN0 3
Table 2
Positions and sequences of PCR primers
Ion transport
system
Accession
no.
Position in the
GenBank sequence
Sequence of the ampli¢cation primers
(5PC3P)
Size of ampli¢ed
fragment (bp)
YEPK2 M14512a 1040^1066 CTGGCTGGAGGCTGTCATCTTCTTCAT 557
1575^1596 GGCTCTGGGGGCTGTCTTCCCT
NaKK1 X04297 1266^1292 CTGGCTGGAGGCTGTCATCTTCTTCAT 560
1802^1825 GTTGGGGCTCCGATGTGTTGGGGT
NaKK2 J05096 12673^12691 CTGGCTGGAGGCTGTCATCTTCTTCAT 557
15043^15066 GGCTCTGGGGGCTGTCTTCTCGCT
NaKK3 X12912 1369^1395 CTGGCTGGAGGCTGTCATCTTCTTCAT 560
M37446 31^55 ATCGGTTGTCGTTGGGGTCCTCGGT
NACA M96368 2160^2183 GGAGAGCACACCAAGTTGGAAGTG 570
2707^2729 ATTGGCTGCGTGGTAGATGGCAG
SERCA2a M23115 1312^1335 GTTGGAGAAGCTACAGAGACTGCT 639
1928^1950 TGACGTCACGTCCTCATCCTGCC
PMCA1 J04027 593^616 GGAGAAGTTTCTGTTGGGGAGGAA 716
1286^1308 GCTTTGCCAATCTGAACAGCCAG
PMCA4 M25874 794^817 GGTCAAGTCGCAACTACCCCAGAA 701
1472^1494 GCTTTGCCAATCTGAACAGCCAG
NHE1 S68616 1985^2007 GACAAGAAGCACTTCCCCATGTG 589
2551^2573 ATCTGGTTCCAGGCTTCCTCGTAG
SCN5A M77235 4263^4284 GCCTTTGAACTACACCATCGTG 570
4808^4832 GCCAAGATGTTGATTTTCTCAGGAC
SCN6A M91556 3465^3488 GCCTTCTGTTTAACGAATCCATGC 524
3964^3988 GAGAGCAATGGACATTTGTAGACTC
RYR2 X98330 13773^13795 CCCATAGAATCATCGCAGTTCAC 681
14430^14453 CAACAACAGCTAATAAGCCAACGG
ITPR1 L38019 6961^6981 AGCATTTCGTTCAACCTGGC 714
7654^7675 CTCTTCTCTGGGTGCAGGAGAG
ITPR2 D26350 7109^7128 AGCATTTCGTTCAACCTGGC 710
7796^7818 GCTGTATTTGAAGCTGGAATTGT
The primer pairs shown amplify speci¢c fragments for each of the ion transporters. NaKK1, NaKK2, NaKK3, sodium pump K subunit
isoforms 1^3; SERCA, sarcoplasmic reticulum Ca2-ATPase; NACA, Na/Ca2-exchanger; PMCA, plasma membrane Ca2-ATPase;
NHE1, Na/H-exchanger; SCN5, tetrodotoxin-insensitive sodium channel; SCN6, atypical sodium channel; RYR, ryanodine recep-
tor; ITPR, inositol 1,4,5-trisphosphate receptor.
aAccession numbers and positions refer to the rat sodium pump isoform K2 with Locus RATATPA2, not to the plasmid.
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The value for the e⁄ciency factor E varies between 0
and 1. At 0, no ampli¢cation is achieved, whereas at
1, one would expect the ideal doubling of the cDNA
in each cycle of ampli¢cation. It is therefore neces-
sary to determine E for each ampli¢cation experi-
ment individually.
This was done by amplifying in parallel to the
unknown samples a sequence of a known vector
that was subjected to a PCR ampli¢cation with an
initial concentration N0 of 2U1034 pmol/100 Wl of
PCR reaction mixture. This amount of vector was
chosen because it would produce by either 20 or 30
PCR cycles a linear area of ampli¢cation of the ex-
pected cDNA band (Eq. 3).
Using [K-32P]dCTP and taking into consideration
the maximally possible incorporation of radioactive
dCMP into the ampli¢ed fragment, the e⁄ciency fac-
tor E can be calculated from the formula
E 

Nn : N0
n
p
31 4
by determining the radioactivity using the Phosphor-
imager BAS 1000. After the determination of E, the
original amount of the sample to be investigated can
be calculated from the equation
N0  Nn : 1 En 5
2.8. Statistical analysis
Values are expressed as means with the associated
standard error mediated (S.E.M.). The t-test for in-
dependent samples and analysis of variance for re-
peated measurements were used for statistical analy-
sis. In some cases the nonparametric Mann^Whitney
U/Wilcoxon rank sum W test was used. Values of
P6 0.05 were considered signi¢cant.
2.9. Preparation of microsomal protein
A total of 50^100 mg derived from the right heart
atrium of hypertensive or normotensive patients was
immediately frozen in liquid nitrogen and ground
with a mortar, also under liquid nitrogen. The tissue
was then suspended in 2 ml of a bu¡er composed of
25 mM imidazole, 1 mM EDTA (pH 7.5), 0.5 mM
phenylmethyl sulfonyl £uoride, 5 Wg/ml pepstatin,
5 Wg/ml leupeptin (all three protease inhibitors from
Boehringer Mannheim, Mannheim, Germany), and
8% (w/v) sucrose. After a further gentle homogeniza-
tion in a Potter Elevejem homogenizer held on ice,
samples were centrifuged at 4000Ug for 20 min at
4‡C. The supernatants were then transferred to new
tubes and centrifuged at 30 000Ug for 1 h at 4‡C.
The resulting pellet was suspended in 500 Wl of 25
mM imidazole, 1 mM EDTA, pH 7.5. After protein
determination [6], samples were stored at 320‡C.
2.10. Binding of [3H]ouabain
A total of 50 Wg of microsomal protein was incu-
bated to equilibrium (60 min) at 30‡C in a mixture
containing 10 mM Tris^HCl (pH 7.4), 5 mM MgCl2,
5 mM Tris/H3PO4, and 50 nM [3H]ouabain. The
total volume of each sample was 100 Wl. Thereafter,
the protein was pelleted by centrifugation at
13 000Ug for 2 min, washed twice with H2O at
4‡C, and dissolved in 200 Wl of 1 M NaOH by in-
cubating at 80‡C for 10 min. After the addition of
200 Wl of 1 M HCl, the samples were mixed with
3.5 ml of scintillation cocktail (Roth, Karlsruhe,
Germany) and counted for radioactivity.
3. Results
3.1. Detection and quanti¢cation of sodium pump-
speci¢c mRNA molecules
A series of experiments had to be carried out in
order to isolate RNA from the tissue, convert the
mRNA therein into single-stranded DNA by the
use of reverse transcriptase and oligo(dT) primer,
and ¢nally amplify by PCR and by the use of speci¢c
primers (Table 2) the cDNA for K1, K2 or K3 iso-
forms of the sodium pump. Although laborious,
these methods are well established and can be carried
out by following standard protocols. Therefore, these
methods have not been described in detail ; rather,
the results are shown in a representative way in
Fig. 1A. This ¢gure shows the autoradiography of
an agarose gel containing K1-, K2- and K3-speci¢c
fragments of cDNA ampli¢ed by PCR in the pres-
ence of [K-32P]dCTP. It is apparent that K1 is the
dominant form of the sodium pump K subunit in
this normotensive patient (Fig. 1A). In the same pa-
tient, K3 is present in a smaller amount, while the K2
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isoform is almost undetectable. In order to quantify
the exact amount of ampli¢ed DNA fragments, we
applied the Phosphorimager technique (Fig. 1B). Us-
ing this method, it is possible to measure the radio-
activity incorporated in a DNA fragment that was
ampli¢ed by PCR in the presence of [K-32P]dCTP.
This can be done by knowing (a) the speci¢c radio-
activity of the [K-32P]dCTP used and (b) the precise
number of [K-32P]dCMP molecules that will be in-
corporated into an ampli¢ed double strand of
DNA. The accuracy of the method was determined
prior to the actual investigation by amplifying vari-
ous known amounts of cDNA coding for the rat K2
subunit of the sodium pump (not shown). Addition-
ally, in order to avoid experimental errors, mRNA of
each patient was reverse transcribed and ampli¢ed by
PCR in three independent experiments. The results
of these experiments are summarized in Table 3. In
agreement with the results shown in Fig. 1A, the K1
cDNA is the predominant form in both normo- and
hypertensive patients and is equally expressed in both
groups of patients. The expression of the K2 isoform,
however, is 5-fold higher in the hypertensive patients
than it is in normotensives. The K3 isoform-speci¢c
cDNA is slightly but signi¢cantly elevated in hyper-
tensive patients (Table 3). The relative expression of
isoforms is summarized in Fig. 2.
3.2. Detection and quanti¢cation of mRNA molecules
coding for various Na+ and/or Ca2+ ion
transporters
The rather unexpected result showing the consid-
erable increase in expression of mRNA coding for K2
and K3 isoforms of the sodium pump (Fig. 2) in the
heart of hypertensive patients prompted us to inves-
tigate the expression of mRNA molecules coding for
other transporters and their isoforms. The emphasis
was placed on the analysis of ion transporting sys-
tems that are involved in Na and Ca2 conduction:
the Ca2-ATPases from the sarcoplasmic reticulum
(SERCA2a) or from the plasma membrane (PMCA1
and PMCA4), the Na/Ca2-exchanger, the Na/
H-exchanger, the tetrodotoxin-insensitive Na
channel SCN5, the atypical Na channel SCN6,
the ca¡eine-sensitive Ca2 release channel ( = ryano-
dine receptor; RYR2), and the inositol 1,4,5-tris-
phosphate-sensitive Ca2-release channels (ITPR1
and ITPR2). The results of this investigation are
summarized in Table 3. For PMCA1 and PMCA4
the double-stranded (ds)DNA ampli¢ed from tissue
of hypertensive patients roughly accounts for twice
the amount ampli¢ed from normotensives (Fig. 2).
The same applies for the Na/Ca2-exchanger. In
contrast, no di¡erences in ampli¢ed dsDNA were
Table 3
Active and passive transport systems of sodium and calcium ampli¢ed from the heart of normotensive and hypertensive patients
Ion transporter Isoform Normotensive patients Hypertensive patients t-Test PCR cycles
Na/K-ATPase K1 0.125 (0.012) 0.152 (0.025) n.s.a 25
K2 0.010 (0.001) 0.045 (0.011) P = 0.008 25
K3 0.055 (0.005) 0.088 (0.015) P = 0.048 25
Na/H-Exchanger NHE1 1.028 (0.044) 1.197 (0.159) n.s. 35
Sodium channel SCN5A 0.600 (0.064) 0.701 (0.099) n.s. 35
SCN6A 1.023 (0.096) 1.414 (0.230) n.s. 35
Na/Ca2-Exchanger NACA 0.073 (0.007) 0.173 (0.028) P = 0.004 25
Ca2-ATPase SERCA2a 0.904 (0.095) 1.175 (0.145) n.s. 25
PMCA1 0.034 (0.006) 0.089 (0.020) P = 0.009b 30
PMCA4 0.080 (0.016) 0.164 (0.027) P = 0.014 30
Calcium channel RYR2 0.526 (0.072) 0.469 (0.090) n.s. 25
ITPR1 0.128 (0.026) 0.141 (0.032) n.s. 25
ITPR2 0.097 (0.019) 0.098 (0.019) n.s. 25
Quanti¢cation of double-stranded DNA (dsDNA) was carried out after reverse transcription of isolated mRNAs and PCR ampli¢ca-
tion of cDNAs by the Phosphorimager technique. For more details see Section 2. Values are given in pmol dsDNA per 100 Wl of
PCR ampli¢cation mixture and are means of 15 measurements (¢ve individuals in each categoryUthree repetitions) þ S.E.M.aNot sig-
ni¢cant.bMann^Whitney U/Wilcoxon rank sum W test.
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found between normotensive and hypertensive pa-
tients for any other ion channels investigated and
for the Na/H-exchanger (Fig. 2).
Because PCR ampli¢cation not only depends on
the amount of the starting template but also on the
e⁄ciency factor E (see Eq. 5 in the Section 2), it was
important to calculate the original amount of ion
transporter-speci¢c mRNA and set this in a relation-
ship to the total amount of RNA isolated. From Fig.
3, it is apparent that the ion transporter-speci¢c
mRNA (ssDNA) is originally present in similar pro-
portions to that after ampli¢cation. Thus, the results
in Fig. 3 con¢rm the results shown in Fig. 2 and
Table 3.
3.3. Ouabain binding experiments
Ouabain binds with high a⁄nity and speci¢city to
the Na,K-ATPase, and, when used in as a radio-
active ligand, is a good tool for estimating the num-
ber of pumps in membrane preparations. Ideally, one
should use the substance in a Scatchard-type experi-
ment in order to extrapolate to the maximum possi-
ble binding. Nevertheless, such experiments require
Fig. 2. Relative expression of sodium or calcium ion transport-
ers. Values (mean þ S.E.M.) of normotensive patients are set to
indicate 100% expression. (A) The sodium transporters listed
are the isoforms of the K subunit of Na/K-ATPase, the so-
dium channel isoforms SCN5a and SCN6a, the Na/H-ex-
changer (NHE1) and the Na/Ca2-exchanger (NACA). (B)
The calcium transporters investigated are the Na/Ca2-ex-
changer (NACA), isoforms 1 and 4 of the plasma membrane
Ca2-ATPase (PMCA1 and PMCA4), isoform 2a of the sar-
coendoplasmic Ca2-ATPase (SERCA), and the calcium chan-
nels ryanodine receptor (RYR2) and isoforms 1 and 2 of the
inositol 1,4,5-trisphosphate receptor (ITPR). *P6 0.05.
Fig. 1. Qualitative and quantitative determination of K1-, K2-
and K3-speci¢c, PCR-ampli¢ed cDNA fragments. (A) The auto-
radiography of an agarose gel shows the presence of K2-speci¢c
cDNA in the heart of a hypertensive patient. (B) The Phos-
phorimager pro¢le further veri¢es this result and allows the
quanti¢cation of the cDNA fragments. The control was a PCR-
ampli¢ed rat K2 cDNA.
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relatively large amounts of protein and could there-
fore not be carried out in the current study. Instead,
ouabain equilibrium binding studies were carried out
as described in Section 2. Whenever su⁄cient protein
was present, measurements were carried out in dupli-
cate or triplicate. Although these measurements are
not as precise as Scatchard binding studies, they still
allow one to obtain a good approximation of the
expression of sodium pumps.
Using microsomes derived from the tissue of either
11 normotensive or 14 hypertensive patients, ouabain
binding was found to be 1.37 þ 0.2 pmol/mg protein
for the normotensive group and 1.99 þ 0.19 pmol/mg
of protein for the hypertensive group. These values
for the two groups are signi¢cantly di¡erent from
each other (P = 0.046).
4. Discussion
Based on clinical observations showing that salt
restriction in the diet results in decreased blood pres-
sure, and the fact that in some hypertensive patients
it is possible to detect elevated Na or Ca2 concen-
trations in the cytosol of their erythrocytes or leuko-
cytes, it was suggested earlier that electrolyte homeo-
stasis of the cell might play an important role in the
pathogenesis of the primary (essential) hypertension
[7]. This physiological change could be taken as an
indication for quantitative or qualitative alterations
in ion transporting systems responsible for Na or
Ca2 homeostasis. Based on this postulate, we exam-
ined the expression levels of mRNA molecules cod-
ing for the isoforms of sodium pump K subunits,
sodium and calcium channels, calcium pumps, and
sodium/calcium and sodium/proton exchangers. The
tissue investigated was taken from the appendage of
the right heart atrium of human patients that had to
undergo cardiac surgery. Although the 50-mg tissue
sample taken was su⁄cient for extraction and detec-
tion of transporter-speci¢c mRNA molecules, it was
not su⁄cient for detection of the corresponding pro-
teins. Nevertheless, it was seen as an advantage at
this stage to investigate the conditions in tissues
where, because of the very short span of time be-
tween tissue removal and mRNA extraction, RNA
degradation was able to be kept to a minimum.
Special emphasis was given to the investigation of
the expression of various K subunit isoforms of the
Na,K-ATPase. The sodium pump plays a key role
in the physiology of animal cells. It is responsible for
the maintenance of the sodium gradient and of the
membrane potential and is involved in regulation of
cell volume. It is the only known receptor for cardiac
glycosides and is thought to be involved in the
pathogenesis of hypertension [8,9]. In rats, extended
treatment with ouabain [10] or a decrease in the so-
dium pump number results in hypertension [3]. A
selective decrease in the expression of the high-a⁄n-
ity ouabain-binding isoform in hypertensive rats has
physiological e¡ects similar to those produced by
treatment with cardiac glycosides or that observed
for increased circulation rates of endogenous sodium
pump inhibitors. In all these cases, the result is a
reduction in sodium pump activity [11].
The expression levels of mRNA for the various
sodium pump isoforms in the heart and their expres-
sion pattern in certain pathological conditions has
been investigated by several groups. The objectives
of these investigations were cardiac diseases like car-
diomyopathy, pressure overload due to valvular de-
fects, and hypertrophy. Fig. 4 summarizes some of
these studies and sets them in relationship to our
current results. In some cases, a decreased expression
Fig. 3. Quanti¢cation of ion transporter-speci¢c mRNAs
(ssDNAs) as a part of the total RNA isolated. The ¢gure
shows the expression of the various mRNAs in hypertensives
(8) and normotensives (a) given in fmol ssDNA per Wg of to-
tal RNA. The inset includes the averaged data þ S.E. calculated
from Eq. 5 (see Section 2) after taking into account the PCR
e⁄ciency factor E. SERCA2a is expressed in a great amount in
the right atrium. Taken together, the three isoforms of the K
subunit mRNAs of the Na,K-ATPase account for half of
this amount.
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of the isoforms was found in diseased hearts [12^14],
in other cases no signi¢cant changes were found in
the expression of isoforms between healthy or dis-
eased hearts [15,16]. In all of the above cases
mRNA expression was mainly investigated in the
left ventricles of the hearts. For detection and quan-
ti¢cation, Northern blot analysis was used in all
cases. All authors reported marked di¡erences in
the expression patterns among the various patients.
Jewell et al. reported a ratio for K1 mRNA to that of
total sodium pump isoforms of 29^79%, for K2
mRNA 7^43%, and for K3 mRNA 11^53% [17].
In the current study, the mRNA for the K1 subunit
isoform of the sodium pump is the predominant
form in the appendage of right atria. This is in
good agreement with results of previous investiga-
tions [12,13,15,16]. In normotensive patients, the K2
is less abundant than the K3. The variability of ex-
pression was, however, less dramatic than in other
investigations. We found a ratio for K1 of 52^72%,
for K2 4^20% and for K3 26^37% (Fig. 4). In hyper-
tensive patients, K1 is also the predominant isoform
and is not expressed at a di¡erent level than in nor-
motensives. The K2 isoform, however, is signi¢cantly
elevated in hypertensives. This subunit mRNA was
rarely present in normotensives (Fig. 1). The K3 iso-
form also shows signi¢cantly higher expression in
hypertensive patients than in normotensives. Thus,
the isoform expression pattern is di¡erent in the
two groups of patients: the ratio K1:K2:K3 changes
from 100:7:40 in normotensives to 100:30:60 in
hypertensives. In the tissue investigated, hypertensive
patients express more sodium pump total K subunit-
speci¢c mRNA (0.89 þ 0.38 fmol for K1+K2+K3
mRNAs per Wg of total RNA) than normotensive
patients (0.58 þ 0.18 fmol/Wg). With membrane prep-
arations from the same area of the heart, speci¢c
ouabain binding is elevated (1.37 þ 0.2 pmol
[3H]ouabain/mg protein for the normotensive group
and 1.99 þ 0.19 pmol [3H]ouabain/mg protein for
the hypertensive group), indicating that increased
mRNA indeed results in increased expression of so-
dium pump protein.
Thus, in the current study, there is no indication
that hypertension is necessarily associated with re-
duced amounts of Na,K-ATPase [3,9]. Assuming
that our observations re£ect a physiologically rele-
vant phenomenon, one has to ask what is the signal
that triggers the elevated expression of sodium
pump-speci¢c mRNAs. One obvious possibility is
that increased expression re£ects a compensatory re-
action to an elevated intracellular Na concentra-
tion. Since in this case [Ca2] should be elevated in
the cytosol due to the decrease of the Na gradient,
one would expect that in hypertension the expression
of Ca2-speci¢c transporters would be also a¡ected.
Increased intracellular [Ca2] in hypertensives has
been shown before [18,19]. For this reason, besides
the sodium pump isoforms and other Na transport-
ing systems, we decided to investigate also the ex-
pression of various Ca2 transporters.
One of the various Na transporting systems is the
Na/H-exchanger, which is thought to be involved
in the pathogenesis of hypertension [20,21]. Elevated
activity of this exchanger would result in elevated
intracellular [Na] and therefore also elevated
[Ca2], a phenomenon observed in investigations of
some patients with hyperactivity of this ion-trans-
porting system [2,22^24]. An increased activity is
not associated with elevated mRNA or protein levels
for this ion transporter [21,25], but rather is possibly
due to changes in the action of G-proteins [26].
Although the latter possibility cannot be addressed
    
Fig. 4. Comparison of various studies. The data shown for ex-
pression of mRNA coding for K1, K2 and K3 subunits of so-
dium pump are normalized. The data of the current study were
obtained by analyzing the expression in the appendage of the
right heart atrium. All other investigators used left ventricles of
human hearts. All studies, except the one of Shamraj et al. who
used tissue from insu⁄cient hearts, are in agreement that K1 is
the predominant mRNA isoform of the sodium pump K sub-
unit. I, insu⁄cient heart with reduced pumping activity; N,
right atrial appendage of normotensives, H, right atrial append-
age of hypertensives; C, control hearts of organically healthy
patients ; P, pressure-overloaded hearts.
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in our investigation, in agreement with the previous
reports we did not detect any hypertension-associ-
ated alterations in the expression of this transporter
(Fig. 2).
The same applies for the expression of the sodium
channels SCN5 and SCN6. No di¡erences were
found between hypertensive or normotensive patients
(Fig. 2 and Table 3). There are three mutations, two
point mutations and a KPQ-deletion in SCN5,
known to be associated with a persistent in£ux of
Na that might play a role in hypertension [27,28].
In our study, we investigated but were not able to
con¢rm the KPQ deletion (not shown).
The Na/Ca2-exchanger is the connecting link
between Na and Ca2 homeostasis and is believed
to play a role in the action of cardiac glycosides or in
the development of hypertension [29]. In our inves-
tigation, the tissue from hypertensive patients ex-
presses 2.4-fold higher Na/Ca2-exchanger-speci¢c
mRNA than the control group (Fig. 2 and Table
3). Changes in the expression of the Na/Ca2-ex-
changer have been investigated previously but the
results are not consistent. While some have demon-
strated increased exchanger-speci¢c mRNA and pro-
tein levels associated with heart diseases [30], others
have failed to con¢rm this observation [31,32]. If we
assume that elevated mRNA is an indication for ele-
vated protein expression, our results are consistent
with our hypothesis that increased expression of
Na or Ca2 transporting systems takes place as a
compensatory mechanism in the face of elevated cy-
tosolic concentrations of these ions. Along these
lines, long-term treatments with ouabain were shown
to cause higher expression of the exchanger [33,34].
Of all active Ca2 transporting systems investi-
gated, di¡erences in expression between normo-
and hypertensives were only found for the plasma
membrane Ca2-ATPase. In hypertensives the
mRNA coding for PMCA1 and PMCA4 isoforms
are signi¢cantly increased (Fig. 2 and Table 3). Plas-
ma membrane Ca2-ATPases have been found to be
elevated on the mRNA level in spontaneously hyper-
tensive rats [35]. Nevertheless, not much is known
about the function and regulation of the various iso-
forms of the plasma membrane Ca2-ATPases. In
contrast to the results for the PMCA isoforms, the
expression of the sarcoendoplasmic Ca2-ATPase
SERCA2a is the same in both groups of patients
(Fig. 2 and Table 3). The same applies for the other
sarcoendoplasmic ion transporting systems investi-
gated here, the Ca2-channels RYR2, ITPR1 and
ITPR2. These systems were preferred for investiga-
tion over others because a reduced expression of
RYR2 mRNA and elevated ITPR1 mRNA in the
ventricle were reported in connection with heart dis-
eases [31,36]. In our investigation, however, no di¡er-
ences were found between normotensive and hyper-
tensive patients.
Currently, we do not have a plausible explanation
as to why all hypertension-related di¡erences in
mRNA expression we have seen thus far are associ-
ated with ion transporters located in the plasma
membrane. The results, however, are consistent
with the idea of compensatory responses to elevated
cytosolic Na and Ca2 concentrations. The reason
for such changes, which have been demonstrated to
occur in connection to hypertension in various inves-
tigations [18,19,37,38], is unclear. One might think
that endogenous cardiac steroids, if produced at
higher levels, might inhibit the sodium pump, caus-
ing elevation of Na and subsequently Ca2 concen-
trations in the cytosol. In such a case, the heart
might respond with upregulation of plasma mem-
brane Na and Ca2 transporters to overcome the
unphysiological imbalance of these ions. Such endog-
enous inhibitors of the sodium pump have been de-
scribed in many investigations [39,40], and it is
thought that their physiological production stimu-
lates heart contraction and that increased biosynthe-
sis might cause hypertension [9,29]. Nevertheless, al-
ternative mechanisms of sodium pump regulation, as
proposed or shown by various investigators [41^45],
or the elevated activity of the Na/H-exchanger [26]
might (also) be linked to cytosolic changes in [Na]
or [Ca2]. Although the investigation presented here,
because of its nature, does not address these possi-
bilities, it is in good agreement with the overall tenor
of numerous investigations suggesting a link between
electrolyte homeostasis and hypertension and en-
courages the continuation of the work under physio-
logically controlled conditions.
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